BioMarin
$87.999876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$87.99
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.11 (+1.28%) Today
$0.00 (0.00%) As of 9:00 AM UTC after-hours
Why Robinhood?
You can buy or sell BioMarin and other stocks, options, and ETFs commission-free!
About BMRN
BioMarin Pharmaceutical Inc. Common Stock, also called BioMarin, is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA. The listed name for BMRN is BioMarin Pharmaceutical Inc. Common Stock.
CEO
Jean-Jacques Bienaimé
Employees
3,001
Headquarters
San Rafael, California
Founded
1997
Market Cap
16.18B
Price-Earnings Ratio
20.15
Dividend Yield
—
Average Volume
2.13M
High Today
$88.80
Low Today
$85.52
Open Price
$85.86
Volume
898.28K
52 Week High
$131.95
52 Week Low
$68.25
Collections
Analyst Ratings
61%
of 23 ratings
Buy
61%
Hold
39%
Sell
0%
BMRN Earnings
-$0.29
$1.14
$2.58
$4.01
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 24, After Hours